

Medlive Completes HK\$4.22 Billion Hong Kong IPO and Rule 144A/Regulation S Offering

07.15.21



Simpson Thacher represented Medlive Technology Co., Ltd. (“Medlive”) in connection with its initial public offering and Rule 144A and Regulation S offering. Medlive offered aggregate of 155,096,000 shares prior to the exercise of the underwriters’ over-allotment option. The base offering size was HK\$4.22 billion (approximately US\$543.4 million). The shares of Medlive are listed on the Main Board of the Hong Kong Stock Exchange. Goldman Sachs and Haitong acted as the joint sponsors, and Goldman Sachs, Haitong and CICC acted as joint global coordinators, joint bookrunners and joint lead managers.

Medlive is the largest online professional physician platform in China in terms of registered physician users. Widely recognized by physicians in China as the most popular professional medical platform, Medlive has become the platform of choice in precision digital healthcare marketing for pharmaceutical and medical device companies in China. The platform participants include physicians, pharmaceutical and medical device companies and patients.

The Simpson Thacher team for the transaction included Celia Lam, Yi Gao, Kai Fan, Quan Zhou, Gary Chan and Linfeng Zhu (Capital Markets); and Jonathan Cantor (Tax).

Team and Contacts

Celia Lam

Of Counsel

celia.lam@stblaw.com

+852-2514-7508

Gary Chan

Associate

gary.chan@stblaw.com

+852-2514-7605

Yi Gao

Partner

ygao@stblaw.com

+852-2514-7620

Jonathan Cantor

Partner

jcantor@stblaw.com

+1-212-455-2237

